NANOSONICS LIMITED (ASX: NAN)
Health care · News and insights
NAN: $2.92 -0.68% · MC: $841M
Latest NAN announcements
Announcement Insights
Nanosonics’ FY27 Buy-Back Nears 3 Million Shares As CORIS Gains FDA Clearance
Nanosonics’ on-market buy-back has continued through FY27, reaching nearly 3 million shares by 17 November under a programme of up to $40 million. Separately, a second FDA clearance for CORIS on 11 November extended the system to high-volume colonoscopes and gastroscopes, advancing the planned US launch; at its 4 November AGM, the company reported FY26 revenue growth of 3% as reported and 6% in constant currency, with constant-currency EBIT up 21%.
Updated 17 Nov 2026, 03:34 PM Sydney time
Sources
Update - Notification of buy-back - NANApplication for quotation of securities - NANNotification of cessation of securities - NANChange of Director's Interest NoticeNanosonics CORIS secures second FDA 510(k) clearanceUpdate - Notification of buy-back - NANUpdate - Notification of buy-back - NANAppointment of Non-Executive Director2026 Annual General Meeting Presentation2026 Annual General Meeting Chairman's & CEO's Addresses2026 AGM Results of MeetingUpdate - Notification of buy-back - NANUpdate - Notification of buy-back - NANUpdate - Notification of buy-back - NANUpdate - Notification of buy-back - NANComments
2026-11-17 · Health care
NAN: $2.92 -0.68% · MC: $841M
Nanosonics bought back 152,373 shares in its latest daily update, bringing the total bought back to nearly 3 million under a buy-back of up to $40 million in FY27; the latest daily volume was higher than the 100,000 shares reported in the previous updates. Separately, CEO Michael Kavanagh’s notice records performance and share appreciation rights lapsing because vesting conditions were not fully met, while a small number of employee-plan shares were issued.
Updated 2026-11-17 15:26
Sources
Update - Notification of buy-back - NANApplication for quotation of securities - NANNotification of cessation of securities - NANChange of Director's Interest NoticeComments
2026-11-11 · Health care
NAN: $2.78 -2.46% · MC: $841M
Nanosonics has secured a second FDA clearance for CORIS, extending the system to additional endoscopes, including high-volume colonoscopes and gastroscopes. The clearance builds on earlier regulatory approvals and advances the company’s planned US launch and broader effort to expand CORIS indications.
Updated 2026-11-11 09:51
Sources
Nanosonics CORIS secures second FDA 510(k) clearanceComments
2026-11-09 · Health care
NAN: $2.89 +0.00% · MC: $841M
Nanosonics bought back 100,000 shares on 6 November, bringing total purchases under its on-market buy-back to approximately 2.8 million shares. The company may buy back shares worth up to $40 million in FY27.
Updated 2026-11-09 19:58
Sources
Update - Notification of buy-back - NANComments
2026-11-05 · Health care
NAN: $2.95 +1.03% · MC: $841M
Nanosonics bought back 100,000 shares on 4 November, taking the total repurchased to approximately 2.7 million under its on-market buy-back of up to $40 million in FY27. The latest daily purchase was smaller than the 150,000 shares reported in an earlier update.
Updated 2026-11-05 17:46
Sources
Update - Notification of buy-back - NANComments
2026-11-04 · Health care
NAN: $2.92 +1.39% · MC: $841M
Nanosonics appointed Julien Sauvagnargues, formerly President and CEO of Olympus’s Americas region, as an independent non-executive director from December, citing his medical technology and endoscopy experience as it advances its CORIS system alongside its trophon business. At its AGM, the company said FY26 revenue grew 3% as reported and 6% in constant currency, while constant-currency EBIT rose 21%; it also reiterated an on-market buy-back of up to $40 million for FY27. Shareholders carried all resolutions listed in the AGM results, including director elections and approvals for executive incentive awards.
Updated 2026-11-04 13:57
Sources
Appointment of Non-Executive Director2026 Annual General Meeting Presentation2026 Annual General Meeting Chairman's & CEO's Addresses2026 AGM Results of MeetingComments
2026-11-02 · Health care
NAN: $2.93 -3.30% · MC: $841M
Nanosonics bought back 100,000 shares on 30 October, bringing the total repurchased to about 2.64 million since the on-market programme began. The company may buy back shares worth up to $40 million in FY27.
Updated 2026-11-02 18:36
Sources
Update - Notification of buy-back - NANComments
2026-10-30 · Health care
NAN: $3.03 +1.34% · MC: $841M
Nanosonics bought back 150,000 shares in its latest daily update, bringing the cumulative total to approximately 2.5 million under its on-market programme, which may purchase up to $40 million of shares in FY27. The latest daily buy-back was larger than the 100,000 shares reported in the previous update.
Updated 2026-10-30 13:52
Sources
Update - Notification of buy-back - NANComments
2026-10-29 · Health care
NAN: $2.99 +0.00% · MC: $841M
Nanosonics bought back 100,000 shares on 27 October, bringing the total bought back to approximately 2.4 million since the on-market program began. The company may buy back shares worth up to $40 million in FY27.
Updated 2026-10-29 08:05
Sources
Update - Notification of buy-back - NANComments
2026-10-28 · Health care
NAN: $2.99 -4.17% · MC: $841M
Nanosonics bought back approximately 121,000 shares on 26 October, bringing total purchases under its on-market buy-back to approximately 2.3 million shares. The company may buy back shares worth up to $40 million during FY27.
Updated 2026-10-28 12:37
Sources
Update - Notification of buy-back - NANComments
Comments